摘要
目的 建立一种快速、灵敏的方法间接测定人血浆和尿样中的羟乙基淀粉浓度。方法 血浆和尿样经三氯乙酸沉淀蛋白，丙酮沉淀羟乙基淀粉后，以三氟乙酸水解羟乙基淀粉，采用己糖激酶法测定水解产物单糖，从而计算血浆和尿中羟乙基淀粉的浓度。结果 测定血浆中羟乙基淀粉方法的线性范围为0.25 ~ 10.0 mg·mL-1，其涵盖实际剂量下血药浓度范围。方法确证各结果均符合相关标准。实验每天可以分析150个样品。结论 本分析方法测试时间短，灵敏度高，血浆用量少，适用于人血浆和尿样中羟乙基淀粉的测定及其药动学研究。
Abstract
OBJECTIVE To develop a rapid and sensitive analytical method for quantification of hydroxyethyl starch in human plasma and urine. METHODS The hydroxyethyl starch was precipitated by actone after deproteinization of the plasma and urine sample with trichloroacetic acid. After the removal of the supernatant，the hydroxyethyl starch precipitate was dissolved and hydrolyzed into monomer with trifluoroacetic acid. After drying and dissolving in phosphate buffer solution，the glucose determination was performed using an enzymatic test based on hexokinase/glucose 6-phosphatese，and the concentration of hydroxyethyl starch was calculated according to the concentration of glucose. RESULTS The linear range of the calibration curve for hydroxyethyl starch was 0.25-10.0 mg·mL-1 which covered the actual plasma concentration. The intra-day and inter-day relative standard deviations of all the check samples were less than 13.2%，and the relative error was in the range of -2.0% to -0.7%. The assay procedure has been validated in term of accuracy，precision，linearity，selectivity and robustness. 150 samples could be analysed per day. CONCLUSION The method is proved to be sensitive，rapid and suitable for the determination of hydroxyethyl starch in human plasma and urine as well as the investigation of hydroxyethyl starch pharmacokinetics.
关键词
羟乙基淀粉200/0.5 /
己糖激酶法 /
血浆浓度
{{custom_keyword}} /
Key words
hydroxyethyl starch 200/0.5 /
hexokinase method /
plasma concentration /
pharmacokinetics
{{custom_keyword}} /
王燕萍 谭波 张逸凡 陈笑艳 钟大放 .
己糖激酶法间接测定人血浆和尿样中的羟乙基淀粉浓度及药动学应用[J]. 中国药学杂志, 2011, 46(15): 1190-1194
WNG Yn-ping;TN o;ZHNG Yi-fn;CHEN Xio-yn;ZHONG D-fng;.
Indirect Determination of Hydroxyethyl Starch in Human Plasma and Urine by Hexokinase Method and Its Application in Pharmacokinetic Study[J]. Chinese Pharmaceutical Journal, 2011, 46(15): 1190-1194
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
［1］ BOLDT J，SUTTNER S. Plasma substitutes ［J］. Minerva Anestesiol，2005，71（12）： 741-758.
［2］ WESTPHAL M，JAMES M F，KOZEK-LANGENECKER S，et al. Hydroxyethyl starches： different products-different effects ［J］. Anesthesiology，2009，111（1）： 187-202.
［3］ World Anti-Doping Agency. The word anti-doping code： The 2010 prohibited list internat- ional standard ［S］. 2009： 5.
［4］ KHLER H，ZSCHIEDRICH H，LINFANTE A，et al. The elimination of hydroxyethyl starch 200/0.5，dextran 40 and oxypolygelatine ［J］. Klin Wochenschr，1982，60（6）： 293-301.
［5］ WILKES N J，WOOLF R L，POWANDA M C，et al. Hydroxyethyl starch in balanced electrolyte solution （Hextend）-pharmacokinetic and pharmacodynamic profiles in healthy volunteers ［J］. Anesth Analg，2002，94（3）： 538-544.
［6］ ZHEN Y，WU X M，DU M Y，et al. Pharmacokinetics of 6% hydroxyethly starch 200/0.5［J］. J Clin Anesthesiol （临床麻醉学杂志），2008，24 （3）： 189-191.
［7］ THYES C，MADJDPOUR C，FRASCAROLO P，et al. Effect of high- and low-molecular-weight low-substituted hydroxyethyl starch on blood coagulation during acute normovolemic hemodilution in pigs ［J］. Anesthesiology，2006，105（6）： 1228-1237.
［8］ REHM M，HALLER M，ORTH V，et al. Changes in blood volume and hematocrit during acute preoperative volume loading with 5% albumin or 6% hetastarch solutions in patients before radical hysterectomy ［J］. Anesthesiology，2001，95（4）： 849-856.
［9］ WAITZINGER J，BEPPERLING F，PABST G，et al. Hydroxyethyl starch （HES） ［130/0.4］，a new HES specification：pharmacokinetics and safety after multiple infusions of 10% solution in healthy volunteers ［J］. Drugs R&D，2003，4 （3）： 149-157.
［10］ JUNGHEINRICH C，SCHARPF R，WARGENAU M，et al. The pharmacokinetics and tolerability of an intravenous infusion of the new hydroxyethyl starch 130/0.4 （6%，500 mL） in mild-to-severe renal impairment ［J］. Anesth Analg，2002，95（3）： 544-551.
［11］ LENZ K，SCHIMETTA W，PLZ W，et al. Intestinal elimination of hydroxyethly starch？［J］. Intensive Care Med，2000，26（6）：733-739.
［12］ LEHMANN G B，ASSKAIL F，BOLL M，et al. HES 130/0.42 shows less alteration of pharmacokinetics than HES 200/0.5 when dosed repeatedly ［J］. Br J Anaesth，2007，98 （5）： 635-644.
［13］ THEVIS M，OPFERMANN G，SCHANZER W. Detection of the plasma volume expander hydroxyethyl starch in human urine ［J］. J Chromatogr B， 2000，744（2）： 345-350.
［14］ DEVENTER K，VAN EENOO P，DELBEKE F T. Detection of hydroxyethyl starch （HES） in human urine by liquid chromatography-mass spectrometry ［J］. J Chromatogr B， 2006，834（1-2）： 217-220.
［15］ GUDDAT S，THEVIS M，THOMAS A，et al. Rapid screening of polysaccharide-based plasma volume expanders dextran and hydroxyethyl starch in human urine by liquid chromatography-tandem mass spectrometry ［J］. Biomed Chromatogr， 2008，22（7）： 695-701.
［16］ GUTIERREZ GALLEGO R，SEGURA J. Rapid screening of plasma volume expanders in urine using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry ［J］. Rapid Commun Mass Spectrum，2004，18（12）： 1324-1330.
［17］ SHAH V P，MIDHA K K，FINDLAY J W，et al. Bioanalytical method validation-A revisit with a decade of progress ［J］. Pharm Res，2000，17（12）： 1551-1557.
［18］ WEIDLER B，VON BORMANN B，SOMMERMEYER K，et al. Pharmacokinetic parameters as criteria for clinical use of hydroxyethyl starch preparations ［J］. Arzneimittelforschung，1991，41（5）： 494-498.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
PDF(718 KB)
